Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Melanoma 1Carcinoma, Transitional Cell 1

Interventions

Specimen Handling 11Magnetic Resonance Spectroscopy 10pembrolizumab 4sacituzumab govitecan 3cabozantinib 3atezolizumab 3Taxes 3Paclitaxel 3Nivolumab 3Gemcitabine 3Biopsy 3eribulin 2erdafitinib 2Radiosurgery 2Platinum 2Ipilimumab 2Docetaxel 2Cisplatin 2Carboplatin 2CTLA-4 Antigen 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1tazemetostat 1sapanisertib 1olaparib 1enfortumab vedotin 1carotuximab 1Tomography, X-Ray Computed 1Suramin 1Panvac-VF 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Transitional Cell × Interleukin-7 × Clear all
NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 14 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡